ATE471936T1 - Als antiangiogene mittel geeignete maleatsalze eines chinazolinderivats - Google Patents

Als antiangiogene mittel geeignete maleatsalze eines chinazolinderivats

Info

Publication number
ATE471936T1
ATE471936T1 AT04806159T AT04806159T ATE471936T1 AT E471936 T1 ATE471936 T1 AT E471936T1 AT 04806159 T AT04806159 T AT 04806159T AT 04806159 T AT04806159 T AT 04806159T AT E471936 T1 ATE471936 T1 AT E471936T1
Authority
AT
Austria
Prior art keywords
chinazoline
antiangiogenic agents
maleate salts
derivative suitable
derivative
Prior art date
Application number
AT04806159T
Other languages
English (en)
Inventor
James Mccabe
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=30776508&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE471936(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of ATE471936T1 publication Critical patent/ATE471936T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/145—Maleic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT04806159T 2003-12-24 2004-12-18 Als antiangiogene mittel geeignete maleatsalze eines chinazolinderivats ATE471936T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0330002.7A GB0330002D0 (en) 2003-12-24 2003-12-24 Quinazoline derivatives
PCT/GB2004/005359 WO2005061488A1 (en) 2003-12-24 2004-12-18 Maleate salts of a quinazoline derivative useful as an antiangiogenic agent

Publications (1)

Publication Number Publication Date
ATE471936T1 true ATE471936T1 (de) 2010-07-15

Family

ID=30776508

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04806159T ATE471936T1 (de) 2003-12-24 2004-12-18 Als antiangiogene mittel geeignete maleatsalze eines chinazolinderivats

Country Status (33)

Country Link
US (6) US20070129387A1 (de)
EP (1) EP1699782B1 (de)
JP (2) JP5009628B2 (de)
KR (1) KR101240872B1 (de)
CN (2) CN1898232B (de)
AR (2) AR046993A1 (de)
AT (1) ATE471936T1 (de)
AU (1) AU2004303590B2 (de)
BR (1) BRPI0417958B8 (de)
CA (1) CA2548662C (de)
CY (1) CY1110730T1 (de)
DE (1) DE602004027833D1 (de)
DK (1) DK1699782T3 (de)
ES (1) ES2345776T3 (de)
GB (1) GB0330002D0 (de)
HK (1) HK1095325A1 (de)
HR (1) HRP20100455T1 (de)
IL (1) IL176308A (de)
MX (1) MXPA06007191A (de)
MY (1) MY145143A (de)
NO (1) NO336613B1 (de)
NZ (1) NZ547547A (de)
PL (1) PL1699782T3 (de)
PT (1) PT1699782E (de)
RS (1) RS51387B (de)
RU (1) RU2425043C2 (de)
SA (1) SA05250464B1 (de)
SI (1) SI1699782T1 (de)
TW (1) TWI339119B (de)
UA (1) UA91332C2 (de)
UY (1) UY28702A1 (de)
WO (1) WO2005061488A1 (de)
ZA (1) ZA200605225B (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EE05345B1 (et) 1999-02-10 2010-10-15 Astrazeneca Ab Kinasoliini derivaadid angiogeneesi inhibiitoritena
CA2473572C (en) * 2002-02-01 2011-05-10 Astrazeneca Ab Quinazoline compounds
GB0330002D0 (en) 2003-12-24 2004-01-28 Astrazeneca Ab Quinazoline derivatives
WO2005092384A2 (en) * 2004-03-23 2005-10-06 Astrazeneca Ab Combination therapy with azd2171 and a platinum anti-tumour agent
GB0523810D0 (en) 2005-11-23 2006-01-04 Astrazeneca Ab Pharmaceutical compositions
WO2007071970A2 (en) * 2005-12-22 2007-06-28 Astrazeneca Ab Combination of azd2171 and pemetrexed
CL2007003158A1 (es) 2006-11-02 2008-05-16 Astrazeneca Ab Procedimiento de preparacion de compuestos derivados de quinazolina o sus sales farmaceuticamente aceptables; compuestos intermediarios; procedimiento de preparacion.
CL2008000070A1 (es) * 2007-01-17 2008-07-25 Lg Life Sciences Ltd Monosal del acido maleico (3-[({1-[(2-amino-9h-purin-9-il)metil]ciclopropil}oxi)metil]-8,8-dimetil-3,7-dioxo-2,4,6-trioxa-3 lambda 5-fosfanon-1-il-pivalato; composicion farmaceutica que comprende a dicha monosal; y uso para el tratamiento del virus h
ES2440565T3 (es) * 2008-12-23 2014-01-29 Merck Patent Gmbh Biomarcadores para inhibidores con actividad anti-angiogénica
KR20140015134A (ko) * 2009-09-25 2014-02-06 교린 세이야꾸 가부시키 가이샤 말레산염 및 그의 결정
JP2015520231A (ja) * 2012-06-25 2015-07-16 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅＬＬＣ セジラニブを含んでいる眼科用局所医薬組成物
US9007866B2 (en) 2013-04-23 2015-04-14 Tessera Inc. Retention optimized memory device using predictive data inversion
EP3062795A4 (de) * 2013-11-01 2017-05-31 Kala Pharmaceuticals, Inc. Kristalline formen therapeutischer verbindungen und verwendungen davon
WO2015066482A1 (en) 2013-11-01 2015-05-07 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
CN105461698A (zh) * 2014-09-12 2016-04-06 杭州普晒医药科技有限公司 西地尼布盐及其晶型、以及其制备方法和药物组合物
WO2017035170A1 (en) * 2015-08-24 2017-03-02 Pliva Hrvatska D.O.O Solid state forms of cediranib maleate
EP3417294B8 (de) 2016-02-15 2022-05-04 Astrazeneca AB Verfahren mit fixer intermittierender dosierung von cediranib
AU2017324251A1 (en) 2016-09-08 2019-03-21 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
AU2017324716B2 (en) 2016-09-08 2020-08-13 KALA BIO, Inc. Crystalline forms of therapeutic compounds and uses thereof
AU2017324713B2 (en) 2016-09-08 2020-08-13 KALA BIO, Inc. Crystalline forms of therapeutic compounds and uses thereof
US10255725B2 (en) * 2016-11-16 2019-04-09 Disney Enterprises, Inc. Augmented reality interactive experience
CN110817898B (zh) * 2018-08-13 2021-09-03 中国科学院大连化学物理研究所 一种具有ats骨架结构的磷酸硅铝分子筛及其制备方法和应用
WO2024003241A1 (en) 2022-06-30 2024-01-04 Astrazeneca Ab Treatment for immuno-oncology resistant subjects with an anti pd-l1 antibody an antisense targeted to stat3 and an inhibitor of ctla-4

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL81307A0 (en) 1986-01-23 1987-08-31 Union Carbide Agricult Method for reducing moisture loss from plants and increasing crop yield utilizing nitrogen containing heterocyclic compounds and some novel polysubstituted pyridine derivatives
IL89029A (en) 1988-01-29 1993-01-31 Lilly Co Eli Fungicidal quinoline and cinnoline derivatives, compositions containing them, and fungicidal methods of using them
US5411963A (en) * 1988-01-29 1995-05-02 Dowelanco Quinazoline derivatives
US5714493A (en) * 1991-05-10 1998-02-03 Rhone-Poulenc Rorer Pharmaceuticals, Inc. Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
US5480883A (en) * 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5721237A (en) 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
US6645969B1 (en) * 1991-05-10 2003-11-11 Aventis Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
CA2102780C (en) * 1991-05-10 2007-01-09 Alfred P. Spada Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
US5710158A (en) 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
CA2091204C (en) 1992-03-11 1997-04-08 Ronald J. Mattson Antiischemic-piperazinyl and piperidinyl-cyclohexanes
GB9323290D0 (en) 1992-12-10 1994-01-05 Zeneca Ltd Quinazoline derivatives
US5700823A (en) 1994-01-07 1997-12-23 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancers
US5736534A (en) 1994-02-23 1998-04-07 Pfizer Inc. 4-heterocyclyl-substituted quinazoline derivatives, processes for their preparation and their use as anti-cancer agents
WO1995024190A2 (en) 1994-03-07 1995-09-14 Sugen, Inc. Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof
DE4436509A1 (de) * 1994-10-13 1996-04-18 Hoechst Schering Agrevo Gmbh Substituierte Spiroalkylamino- und alkoxy-Heterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Schädlingsbekämpfungsmittel und Fungizide
GB9505651D0 (en) 1995-03-21 1995-05-10 Agrevo Uk Ltd AgrEvo UK Limited
US6046206A (en) * 1995-06-07 2000-04-04 Cell Pathways, Inc. Method of treating a patient having a precancerous lesions with amide quinazoline derivatives
GB9514265D0 (en) 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
JP4009681B2 (ja) 1995-11-07 2007-11-21 キリンファーマ株式会社 血小板由来成長因子受容体自己リン酸化を阻害するキノリン誘導体ならびにキナゾリン誘導体およびそれらを含有する薬学的組成物
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
DE19614718A1 (de) 1996-04-15 1997-10-16 Hoechst Schering Agrevo Gmbh Substituierte Pyridine/Pyrimidine, Verfahren zu ihrer Herstellung, und ihre Verwendung als Schädlingsbekämpfungsmittel
GB9707800D0 (en) 1996-05-06 1997-06-04 Zeneca Ltd Chemical compounds
ID19609A (id) 1996-07-13 1998-07-23 Glaxo Group Ltd Senyawa-senyawa heterosiklik
EP0837063A1 (de) 1996-10-17 1998-04-22 Pfizer Inc. 4-Aminoquinazolinderivate
US6225318B1 (en) * 1996-10-17 2001-05-01 Pfizer Inc 4-aminoquinazolone derivatives
EP0984692A4 (de) 1997-05-30 2001-02-21 Merck & Co Inc Angiogenese-inhibitoren
ZA986729B (en) * 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
DE69838172T2 (de) 1997-08-22 2008-04-10 Astrazeneca Ab Oxindolylchinazolinderivate als angiogenesehemmer
US6162804A (en) * 1997-09-26 2000-12-19 Merck & Co., Inc. Tyrosine kinase inhibitors
GB9721437D0 (en) 1997-10-10 1997-12-10 Glaxo Group Ltd Heteroaromatic compounds and their use in medicine
GB9800569D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
GB9800575D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
US6172071B1 (en) 1998-07-30 2001-01-09 Hughes Institute Lipid-lowering quinazoline derivative
US6184226B1 (en) 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
GB2345486A (en) 1999-01-11 2000-07-12 Glaxo Group Ltd Heteroaromatic protein tyrosine kinase inhibitors
JP3270834B2 (ja) 1999-01-27 2002-04-02 ファイザー・プロダクツ・インク 抗がん剤として有用なヘテロ芳香族二環式誘導体
UA71945C2 (en) 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
EE05345B1 (et) * 1999-02-10 2010-10-15 Astrazeneca Ab Kinasoliini derivaadid angiogeneesi inhibiitoritena
DE19911509A1 (de) 1999-03-15 2000-09-21 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
TWI262914B (en) * 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
PE20010306A1 (es) 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
EE05107B1 (et) 1999-10-19 2008-12-15 Merck & Co., Inc. Türosiinkinaasi pärssiv ühend, seda sisaldav farmatseutiline kompositsioon ning ühendi kasutamine
PL203782B1 (pl) * 1999-11-05 2009-11-30 Astrazeneca Ab Pochodne chinazoliny,sposoby ich wytwarzania,ich kompozycje farmaceutyczne oraz ich zastosowania
GB0008269D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
WO2003014732A1 (en) * 2001-08-10 2003-02-20 Symyx Technologies, Inc. Apparatuses and methods for creating and testing pre-formulations and systems for same
CA2473572C (en) 2002-02-01 2011-05-10 Astrazeneca Ab Quinazoline compounds
GB0330002D0 (en) * 2003-12-24 2004-01-28 Astrazeneca Ab Quinazoline derivatives
GB0406446D0 (en) * 2004-03-23 2004-04-28 Astrazeneca Ab Combination therapy
GB0523810D0 (en) * 2005-11-23 2006-01-04 Astrazeneca Ab Pharmaceutical compositions

Also Published As

Publication number Publication date
CN102153543A (zh) 2011-08-17
UA91332C2 (uk) 2010-07-26
JP2011088936A (ja) 2011-05-06
US20150025091A1 (en) 2015-01-22
BRPI0417958B8 (pt) 2021-05-25
RU2006126782A (ru) 2008-01-27
AR104979A2 (es) 2017-08-30
ZA200605225B (en) 2007-05-30
NO20062703L (no) 2006-07-20
PL1699782T3 (pl) 2010-10-29
HK1095325A1 (en) 2007-05-04
AU2004303590A1 (en) 2005-07-07
KR101240872B1 (ko) 2013-03-07
US20180170913A1 (en) 2018-06-21
CN1898232A (zh) 2007-01-17
ES2345776T3 (es) 2010-10-01
US9890140B2 (en) 2018-02-13
KR20060127899A (ko) 2006-12-13
PT1699782E (pt) 2010-08-04
CY1110730T1 (el) 2015-06-10
JP5009628B2 (ja) 2012-08-22
MY145143A (en) 2011-12-30
MXPA06007191A (es) 2006-08-23
RS51387B (en) 2011-02-28
RU2425043C2 (ru) 2011-07-27
SA05250464B1 (ar) 2008-08-27
US20170000791A1 (en) 2017-01-05
AR046993A1 (es) 2006-01-04
TW200524593A (en) 2005-08-01
DE602004027833D1 (de) 2010-08-05
IL176308A (en) 2013-03-24
US9556151B2 (en) 2017-01-31
CN102153543B (zh) 2013-01-02
NO336613B1 (no) 2015-10-12
BRPI0417958B1 (pt) 2019-02-05
AU2004303590B2 (en) 2009-07-30
US20190375730A1 (en) 2019-12-12
IL176308A0 (en) 2006-10-05
US20100298357A1 (en) 2010-11-25
TWI339119B (en) 2011-03-21
EP1699782B1 (de) 2010-06-23
NZ547547A (en) 2009-08-28
WO2005061488A1 (en) 2005-07-07
US20070129387A1 (en) 2007-06-07
CN1898232B (zh) 2011-08-17
US8859570B2 (en) 2014-10-14
SI1699782T1 (sl) 2010-09-30
GB0330002D0 (en) 2004-01-28
CA2548662C (en) 2013-09-03
CA2548662A1 (en) 2005-07-07
EP1699782A1 (de) 2006-09-13
UY28702A1 (es) 2005-07-29
HRP20100455T1 (hr) 2010-09-30
DK1699782T3 (da) 2010-08-30
BRPI0417958A (pt) 2007-03-27
JP2007517008A (ja) 2007-06-28

Similar Documents

Publication Publication Date Title
ATE471936T1 (de) Als antiangiogene mittel geeignete maleatsalze eines chinazolinderivats
DE602005008084D1 (de) Als antikonvulsive mittel geeignete neue benzokondensierte heteroarylsulfamidderivate
DE602004015724D1 (de) Diazepinoindolderivate als kinaseinhibitoren
DE602004024420D1 (de) Chinazolinderivate als antitumormittel
ATE378049T1 (de) Nicotinamid-derivate als pde4-hemmer
ATE420076T1 (de) Indozolonderivate als 11b-hsd1-inhibitoren
ATE426599T1 (de) Thiazolylpiperidin derivate als mtp inhibitoren
NO20054224D0 (no) Nye 2-pyridinkarboksamidderivater
ATE489372T1 (de) Als mikrobiozide geeignete heterocyclische amidderivate
ATE452631T1 (de) N-2-adamantanyl-2-phenoxy-acetamid-derivate als 11-betahydroxysteroid-dehydrogenase-hemmer
ATE540936T1 (de) Substituierte 2-alkyl-chinazolinonderivate als parp-hemmer
DK1515969T3 (da) Spiroindolinpiperidinderivater
ATE521595T1 (de) Cyclohexylaminisochinolonderivate als rho-kinase- inhibitor
ATE333446T1 (de) Pyrimidin-4-onderivat als ldl-pla2 inhibitor
ATE529428T1 (de) Thioxanthinderivate als myeloperoxidaseinhibitoren
DE602004027343D1 (de) Wasserzuführungsvorrichtung eines Geschirrspülers
ATE453625T1 (de) 4-pyridinylmethylsulfonamidderivate als fungizidwirksame pflanzenschutzmittel
ATE308543T1 (de) Piperidinderivate
DK1626964T3 (da) Nye benzimidazolderivater
DE60323599D1 (de) Formangepasste Zähne eines Fräsers
DE602004005403D1 (de) Motorgetriebene Arbeitsmachine
ATE372323T1 (de) Als antivirale mittel geeignete 4- carboxypyrazolderivate
NO20021557D0 (no) Anordning ved sveisemaskin
ATE440821T1 (de) Isochinolinderivate als mao-b inhibitoren
ATE384530T1 (de) 4-aminochinolin-3-carbonsäureamid-derivate als pde4-hemmer

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1699782

Country of ref document: EP